Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.25 USD | 0.00% | -3.11% | -21.56% |
05-30 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
05-30 | Bristol Myers: FDA approval for Breyanzi | CF |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- BMY Stock
- Revisions Bristol-Myers Squibb Company